knowledge -WSS

knowledge

author：focus 2025-09-30 17:46:04 - browse：6

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

hotspot

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medicare Advantage coverage denials need scrutiny, senators say

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Health tech startups drop sharply from 2021 highs

Why do women spend more than men on medical expenses?

hotspot

knowledge

hotspot

How to save PrEP access — and even expand it

STAT Virtual Event: JPM Recap, Live!

Walensky prepares to leave CDC — and Congress — behind

Researchers use wearables data and AI to predict preterm birth risk

In Memoriam: Notable people who died in 2023

Medicare Advantage coverage denials need scrutiny, senators say

Apple is now the first public company to be valued at $3 trillion

Allen Institute goes after foundational questions, CEO Costa says

ChatGPT in medicine: STAT answers readers' burning questions

Data show record exodus of life scientists from academia

leisure time

Covid vaccines: Private market messier than government rollout

Study suggests new cause of Down syndrome: cells linked to aging

Researchers use wearables data and AI to predict preterm birth risk

At JPM 2024, hospital systems pitch financial strength to investors

Hospital chaplains balance Covid safety with patients’ spiritual needs

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

leisure time

focus

focus